Seroatlas · Human Serome Atlas

PLPPR5

Phospholipid phosphatase-related protein type 5

Also known as: LPPR5, PAP2, PAP2D, PLPR5_HUMAN, PRG5

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q32ZL2
Gene: PLPPR5
Ensembl: ENSG00000117598
Chromosome: 1
Canonical length: 321 aa
Protein class: Predicted membrane proteins
Subcellular location: Plasma membrane,Cytosol

OverviewNCBI Gene

The protein encoded by this gene is a type 2 member of the phosphatidic acid phosphatase (PAP) family. All type 2 members of this protein family contain 6 transmembrane regions, and a consensus N-glycosylation site. PAPs convert phosphatidic acid to diacylglycerol, and function in de novo synthesis of glycerolipids as well as in receptor-activated signal transduction mediated by phospholipase D. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

321 residues, UniProt reviewed canonical sequence.

>Q32ZL2|PLPPR5
     1  MPLLPAALTS SMLYFQMVIM AGTVMLAYYF EYTDTFTVNV QGFFCHDSAY RKPYPGPEDS
    61  SAVPPVLLYS LAAGVPVLVI IVGETAVFCL QLATRDFENQ EKTILTGDCC YINPLVRRTV
   121  RFLGIYTFGL FATDIFVNAG QVVTGNLAPH FLALCKPNYT ALGCQQYTQF ISGEEACTGN
   181  PDLIMRARKT FPSKEAALSV YAAMYLTMYI TNTIKAKGTR LAKPVLCLGL MCLAFLTGLN
   241  RVAEYRNHWS DVIAGFLVGI SIAVFLVVCV VNNFKGRQAE NEHIHMDNLA QMPMISIPRV
   301  ESPLEKVTSV QNHITAFAEV T

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PLPPR5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 6
Mean surface accessibility (rSASA): 0.36
Highest tissue expression: 6.5 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 6.5 nTPM
basal ganglia: 5.7 nTPM
hippocampal formation: 5.5 nTPM
amygdala: 5.3 nTPM
hypothalamus: 4.4 nTPM
testis: 1.9 nTPM

Single-cell type

thyrotrophs: 253 nCPM
oligodendrocyte progenitor cells: 191 nCPM
retinal amacrine cells: 148 nCPM
lactotrophs: 137 nCPM
brain inhibitory neurons: 114 nCPM
brain excitatory neurons: 79 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hypothalamus: 16 nTPM
cerebral cortex: 14 nTPM
hippocampal formation: 14 nTPM
basal ganglia: 13 nTPM
amygdala: 10 nTPM
midbrain: 9.7 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.65
gnomAD pLI: 0.06
DepMap mean gene effect: -0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

phosphatidate phosphatase activity

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PLPPR5 as an antibody target. Whether an autoantibody or antibody against PLPPR5 could matter depends on whether native PLPPR5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PLPPR5 is annotated at the cell surface, where native PLPPR5 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PLPPR5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...